---
schema_version: "secwatch.filing_event.v1"
accession: "0001607062-23-000434"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2023-09-18T23:59:59+00:00"
generated_at: "2026-06-10T14:49:26.127611+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma enters $175K promissory note and $10M equity line with Coventry

## Summary
- Net proceeds $148,750 after $26,250 original issue discount; note matures March 2025.
- Note carries 10% interest, convertible upon default at 90% of lowest 20-day trading price.
- Equity line allows draw downs at 80% of lowest price over prior 10 business days; max $250K per draw.
- Coventry receives 125,000 commitment shares; registration statement to cover up to 1,126,954 shares.
- Draw downs limited to 200% of average daily dollar traded value; beneficial ownership cap 4.99%.

## SEC filing metadata
- accession: 0001607062-23-000434
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2023-09-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000160706223000434/0001607062-23-000434-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000160706223000434/rgbp091823form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607062-23-000434
- JSON: https://secwatch.observer/filing/0001607062-23-000434.json
- Plain text: https://secwatch.observer/filing/0001607062-23-000434.txt

## Key facts
- Material Agreements
  Regen BioPharma Inc entered into Purchase Agreement with Coventry Enterprises, LLC valued at $175,000 (effective 2023-09-12).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Coventry Enterprises, LLC
  - Value: $175,000
  - Effective: 2023-09-12
  source text: Effective September 12, 2023 Regen Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Coventry Enterprises, LLC (“Coventry”), pursuant to which Coventry Enterprises purchased a 10% unsecured promissory Note (the “Note”) from the Company in the principal amount of $175,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1589150/000160706223000434/0001607062-23-000434-index.htm
- Material Agreements
  Regen BioPharma Inc entered into Registration Rights Agreement with Coventry (effective 2023-09-12).
  - Action: entry
  - Counterparty: Coventry
  - Effective: 2023-09-12
  source text: In connection with the Equity Line Agreement the Company also entered into a Registration Rights Agreement, dated September 12, 2023 with Coventry (the “Registration Rights Agreement”), pursuant to which the Company agreed to register for resale under the Securities Act of 1933 shares issuable in accordance with the Equity Line Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1589150/000160706223000434/0001607062-23-000434-index.htm
- Material Agreements
  Regen BioPharma Inc entered into common stock purchase agreement with Coventry valued at up to Ten Million Dollars ($10,000,000) (effective 2023-09-12).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Coventry
  - Value: up to Ten Million Dollars ($10,000,000)
  - Effective: 2023-09-12
  source text: On September 12, 2023 the Company entered into a common stock purchase agreement (the “Equity Line Agreement”) with Coventry providing for an equity financing facility (the “Equity Line”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1589150/000160706223000434/0001607062-23-000434-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.